Table of Content
1 Introduction
1.1 Objective of the Study
1.2 Definition of the Market
1.3 Market Scope
1.3.1 Market Segment by Type, Application and Marketing Channel
1.3.2 Major Regions Covered (North America, Europe, Asia Pacific, Mid East & Africa)
1.4 Years Considered for the Study (2015-2028)
1.5 Currency Considered (U.S. Dollar)
1.6 Stakeholders
2 Key Findings of the Study
3 Market Dynamics
3.1 Driving Factors for this Market
3.2 Factors Challenging the Market
3.3 Opportunities of the Global Gene Therapy for Age-related Macular Degeneration Market (Regions, Growing/Emerging Downstream Market Analysis)
3.4 Technological and Market Developments in the Gene Therapy for Age-related Macular Degeneration Market
3.5 Industry News by Region
3.6 Regulatory Scenario by Region/Country
3.7 Market Investment Scenario Strategic Recommendations Analysis
4 Value Chain of the Gene Therapy for Age-related Macular Degeneration Market
4.1 Value Chain Status
4.2 Upstream Raw Material Analysis
4.3 Midstream Major Company Analysis (by Manufacturing Base, by Product Type)
4.4 Distributors/Traders
4.5 Downstream Major Customer Analysis (by Region)
5 Global Gene Therapy for Age-related Macular Degeneration Market-Segmentation by Type
5.1 Subretinal
5.2 Intravitreal
5.3 Unspecified
6 Global Gene Therapy for Age-related Macular Degeneration Market-Segmentation by Application
6.1 Monotherapy
6.2 Combination Therapy
7 Global Gene Therapy for Age-related Macular Degeneration Market-Segmentation by Marketing Channel
7.1 Traditional Marketing Channel (Offline)
7.2 Online Channel
8 Competitive Intelligence - Company Profiles
8.1 AGTC
8.1.1 AGTC Profile
8.1.2 AGTC Sales, Growth Rate and Global Market Share from 2015-2020
8.1.3 AGTC Product/Solution Launches and Enhancements Analysis
8.1.4 AGTC Business Overview/Recent Development/Acquisitions
8.2 RetroSense Therapeutics
8.2.1 RetroSense Therapeutics Profile
8.2.2 RetroSense Therapeutics Sales, Growth Rate and Global Market Share from 2015-2020
8.2.3 RetroSense Therapeutics Product/Solution Launches and Enhancements Analysis
8.2.4 RetroSense Therapeutics Business Overview/Recent Development/Acquisitions
8.3 REGENXBIO
8.3.1 REGENXBIO Profile
8.3.2 REGENXBIO Sales, Growth Rate and Global Market Share from 2015-2020
8.3.3 REGENXBIO Product/Solution Launches and Enhancements Analysis
8.3.4 REGENXBIO Business Overview/Recent Development/Acquisitions
9 Global Gene Therapy for Age-related Macular Degeneration Market-Segmentation by Geography
10 North America
10.1 North America Gene Therapy for Age-related Macular Degeneration Production, Ex-factory Price, Revenue, Gross Margin (%) and Gross Analysis from 2015-2020
10.2 North America Gene Therapy for Age-related Macular Degeneration Consumption, Terminal Price, Consumption Value and Channel Margin Analysis from 2015-2020
10.3 North America Gene Therapy for Age-related Macular Degeneration Production Analysis from 2015-2020
10.4 North America Gene Therapy for Age-related Macular Degeneration Consumption Analysis from 2015-2020
10.5 North America Gene Therapy for Age-related Macular Degeneration Import and Export from 2015-2020
10.6 North America Gene Therapy for Age-related Macular Degeneration Value, Production and Market Share by Type (2015-2020)
10.7 North America Gene Therapy for Age-related Macular Degeneration Consumption, Value and Market Share by Application (2015-2020)
10.8 North America Gene Therapy for Age-related Macular Degeneration by Country (United States, Canada)
10.8.1 North America Gene Therapy for Age-related Macular Degeneration Sales by Country (2015-2020)
10.8.2 North America Gene Therapy for Age-related Macular Degeneration Consumption Value by Country (2015-2020)
10.9 North America Gene Therapy for Age-related Macular Degeneration Market PEST Analysis
11 Europe
11.1 Europe Gene Therapy for Age-related Macular Degeneration Production, Ex-factory Price, Revenue, Gross Margin (%) and Gross Analysis from 2015-2020
11.2 Europe Gene Therapy for Age-related Macular Degeneration Consumption, Terminal Price, Consumption Value and Channel Margin Analysis from 2015-2020
11.3 Europe Gene Therapy for Age-related Macular Degeneration Production Analysis from 2015-2020
11.4 Europe Gene Therapy for Age-related Macular Degeneration Consumption Analysis from 2015-2020
11.5 Europe Gene Therapy for Age-related Macular Degeneration Import and Export from 2015-2020
11.6 Europe Gene Therapy for Age-related Macular Degeneration Value, Production and Market Share by Type (2015-2020)
11.7 Europe Gene Therapy for Age-related Macular Degeneration Consumption, Value and Market Share by Application (2015-2020)
11.8 Europe Gene Therapy for Age-related Macular Degeneration by Country (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium)
11.8.1 Europe Gene Therapy for Age-related Macular Degeneration Sales by Country (2015-2020)
11.8.2 Europe Gene Therapy for Age-related Macular Degeneration Consumption Value by Country (2015-2020)
11.9 Europe Gene Therapy for Age-related Macular Degeneration Market PEST Analysis
12 Asia-Pacific
12.1 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Production, Ex-factory Price, Revenue, Gross Margin (%) and Gross Analysis from 2015-2020
12.2 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Consumption, Terminal Price, Consumption Value and Channel Margin Analysis from 2015-2020
12.3 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Production Analysis from 2015-2020
12.4 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Consumption Analysis from 2015-2020
12.5 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Import and Export from 2015-2020
12.6 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Value, Production and Market Share by Type (2015-2020)
12.7 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Consumption, Value and Market Share by Application (2015-2020)
12.8 Asia-Pacific Gene Therapy for Age-related Macular Degeneration by Country (China, Japan, South Korea, Australia, India, Taiwan, Indonesia, Thailand, Philippines, Malaysia)
12.8.1 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Sales by Country (2015-2020)
12.8.2 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Consumption Value by Country (2015-2020)
12.9 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market PEST Analysis
13 Latin America
13.1 Latin America Gene Therapy for Age-related Macular Degeneration Production, Ex-factory Price, Revenue, Gross Margin (%) and Gross Analysis from 2015-2020
13.2 Latin America Gene Therapy for Age-related Macular Degeneration Consumption, Terminal Price, Consumption Value and Channel Margin Analysis from 2015-2020
13.3 Latin America Gene Therapy for Age-related Macular Degeneration Production Analysis from 2015-2020
13.4 Latin America Gene Therapy for Age-related Macular Degeneration Consumption Analysis from 2015-2020
13.5 Latin America Gene Therapy for Age-related Macular Degeneration Import and Export from 2015-2020
13.6 Latin America Gene Therapy for Age-related Macular Degeneration Value, Production and Market Share by Type (2015-2020)
13.7 Latin America Gene Therapy for Age-related Macular Degeneration Consumption, Value and Market Share by Application (2015-2020)
13.8 Latin America Gene Therapy for Age-related Macular Degeneration by Country (Brazil, Mexico, Argentina, Columbia, Chile)
13.8.1 Latin America Gene Therapy for Age-related Macular Degeneration Sales by Country (2015-2020)
13.8.2 Latin America Gene Therapy for Age-related Macular Degeneration Consumption Value by Country (2015-2020)
13.9 Latin America Gene Therapy for Age-related Macular Degeneration Market PEST Analysis
14 Middle East & Africa
14.1 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Production, Ex-factory Price, Revenue, Gross Margin (%) and Gross Analysis from 2015-2020
14.2 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Consumption, Terminal Price, Consumption Value and Channel Margin Analysis from 2015-2020
14.3 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Production Analysis from 2015-2020
14.4 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Consumption Analysis from 2015-2020
14.5 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Import and Export from 2015-2020
14.6 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Value, Production and Market Share by Type (2015-2020)
14.7 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Consumption, Value and Market Share by Application (2015-2020)
14.8 Middle East & Africa Gene Therapy for Age-related Macular Degeneration by Country (Saudi Arabia, UAE, Egypt, Nigeria, South Africa)
14.8.1 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Sales by Country (2015-2020)
14.8.2 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Consumption Value by Country (2015-2020)
14.9 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market PEST Analysis
15 Future Forecast of the Global Gene Therapy for Age-related Macular Degeneration Market from 2020-2028
15.1 Future Forecast of the Global Gene Therapy for Age-related Macular Degeneration Market from 2020-2028 Segment by Region
15.2 Global Gene Therapy for Age-related Macular Degeneration Production and Growth Rate Forecast by Type (2020-2028)
15.3 Global Gene Therapy for Age-related Macular Degeneration Consumption and Growth Rate Forecast by Application (2020-2028)
16 Appendix
16.1 Methodology
16.2 Research Data Source
